Clinical trial of Kanglaite injection combined with gemcitabine injection and tegafur-gimeracil-oteracil potassium capsule in the treatment of advanced pancreatic cancer
10.13699/j.cnki.1001-6821.2018.02.005
- VernacularTitle:康莱特注射液联合吉西他滨注射液和替吉奥胶囊治疗晚期胰腺癌的临床研究
- Author:
Xin-Feng ZHANG
1
;
Cui-Xia QIAO
;
Xu-Feng CHENG
;
Qi LIU
;
Qi-Long GAO
;
Xu-Chu YANG
;
Huai-Zhang WANG
Author Information
1. 郑州大学附属肿瘤医院中西医科
- Keywords:
pancreatic cancer;
Kanglaite injection;
gemcitabine injection;
tegafur-gimeracil-oteracil potassium capsule
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(2):111-113
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of Kanglaite injection combined with emcitabine injection and tegafur-gimeracil-oteracil potassium capsule in the treatment of advanced pancreatic cancer(PC).Methods A total of 45 patients with advanced pancreatic cancer were randomly divided into treatment group (n =23) and control group (n =22).The control group was given gemcitabine (1000 mg · m2,iv gtt,at day 1 and day 8) and tegafur-gimeracil-oteracil potassium capsule (1.25 m2 ≤ body surface area ＜ 1.5 m2,40 mg,bid;body surface area≥ 1.5 m2,50 mg,bid,day 1-day 14).The treatment group was treated with Kanglaite (20 g,qd,day 1-day 14) on the basis of control group.Both groups were treated for more than 4 cycles.The clinical benefit rate (CBR),overall survival (OS) and the adverse drug reactions (ADRs) were evaluated between the two groups.Results The CBR of treatment group and control group were 78.26％ (18 cases/23 cases) and 50.00％ (11 cases/22 cases) respectively,with significant difference (P ＜ 0.05).The median OS of treatment group and control group were 6.67 months and 5.60 months,respectively,with significant difference (P ＜ 0.05).The ADRs in the treatment group and control group were bone marrow depression,fatigue,gastrointestinal reaction,abnormal liver and kidney function and skin reaction,and there was no significant difference in the incidence of ADRs reactions between the two groups (P ＞ 0.05).Conclusion Kanglaite combined gemcitabine and tegafur-gimeracil-oteracil potassium is effective and safe in the treatment of advanced pancreatic cancer,with a longer OS,a higher incidence of clinical benefit and less ADRs.
